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Background: Despite the availability of national and international guidelines, evidence suggests 
that chronic obstructive pulmonary disease (COPD) treatment is not always prescribed accord-
ing to recommendations. This study evaluated the current management of patients with COPD 
using a large UK primary-care database.
Methods: This analysis used electronic patient records and patient-completed questionnaires 
from the Optimum Patient Care Research Database. Data on current management were analyzed 
by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) group and presence or 
absence of a concomitant asthma diagnosis, in patients with a COPD diagnosis at 35 years 
of age and with spirometry results supportive of the COPD diagnosis.
Results: A total of 24,957 patients were analyzed, of whom 13,557 (54.3%) had moderate air-
flow limitation (GOLD Stage 2 COPD). The proportion of patients not receiving pharmacologic 
treatment for COPD was 17.0% in the total COPD population and 17.7% in the GOLD Stage 2 
subset. Approximately 50% of patients in both cohorts were receiving inhaled corticosteroids 
(ICS), either in combination with a long-acting β
2
-agonist (LABA; 26.7% for both cohorts) or a 
LABA and a long-acting muscarinic antagonist (LAMA; 23.2% and 19.9%, respectively). ICS + 
LABA and ICS + LABA + LAMA were the most frequently used treatments in GOLD Groups A 
and B. Of patients without concomitant asthma, 53.7% of the total COPD population and 50.2% 
of the GOLD Stage 2 subset were receiving ICS. Of patients with GOLD Stage 2 COPD and 
no exacerbations in the previous year, 49% were prescribed ICS. A high proportion of GOLD 
Stage 2 COPD patients were symptomatic on their current management (36.6% with modified 
Medical Research Council score 2; 76.4% with COPD Assessment Test score 10).
Conclusion: COPD is not treated according to GOLD and National Institute for Health and 
Care Excellence recommendations in the UK primary-care setting. Some patients receive no 
treatment despite experiencing symptoms. Among those on treatment, most receive ICS irre-
spective of severity of airflow limitation, asthma diagnosis, and exacerbation history. Many 
patients on treatment continue to have symptoms.
Keywords: COPD, UK primary-care setting, prescribing patterns, inhaled corticosteroids, 
bronchodilators
Introduction
Chronic obstructive pulmonary disease (COPD) is a complex disease characterized 
by pulmonary as well as extrapulmonary effects. As airflow limitation poorly relates 
to other important clinical outcomes in COPD, the Global Initiative for Chronic 
 Obstructive Lung Disease (GOLD) 2014 strategy advocates a combined assessment 
to estimate current symptoms and future risk of exacerbations (Figure S1).1 In the UK, 
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the National Institute for Health and Care Excellence (NICE) 
also recommends a multidimensional assessment to guide 
treatment of COPD.2
In COPD, pharmacologic therapy is used to reduce symp-
toms, reduce frequency and severity of exacerbations, and 
improve health status and exercise tolerance.1 Bronchodilator 
medications are central to the pharmacologic management of 
COPD.1 Short-acting bronchodilators are used for immediate 
relief from symptoms; one or more long-acting broncho-
dilators (long-acting β
2
-agonists [LABAs] or long-acting 
muscarinic antagonists [LAMAs]) are recommended for 
long-term maintenance therapy in patients with moderate-
to-severe COPD.1–3 Combining bronchodilators of different 
pharmacologic classes has the potential to improve efficacy, 
without increasing the risk of side effects, compared with 
increasing the dose of a single bronchodilator.1,4–7
Whilst inhaled corticosteroids (ICS) are the corner-
stone of asthma management, their role in COPD remains 
 controversial.8–11 In COPD, the role of ICS is primarily to 
reduce the risk of exacerbations.12 Evidence from subset 
analyses of large clinical trials indicates the efficacy of 
LABA/ICS in patients with moderate or severe COPD,13 
but the benefit due to the ICS component appears small 
compared with that of the LABA component.11,12 Further, 
the use of ICS has been associated with local and systemic 
side effects, including skin thinning and easy bruising,12 oral 
candidiasis,12,13 increased risk of pneumonia,12–15 osteoporo-
sis, early onset diabetes, cataracts,12 and tuberculosis.16
The GOLD 2014 strategy recommends the addition of a 
second bronchodilator in symptomatic patients with moder-
ate airflow limitation, reserving the use of ICS, in addition 
to a maintenance therapy with a LABA, and/or a LABA and 
a LAMA, for patients with severe or very severe airflow 
limitation and/or two or more exacerbations per year.1 In line 
with GOLD, national guidelines such as those developed by 
NICE recommend ICS in addition to a LABA as first choice 
in patients with severe airflow limitation (forced expiratory 
volume in 1 second [FEV
1
] ,50% of predicted) and recur-
rent exacerbations and/or breathlessness.2 However, there is 
evidence to suggest that treatment is not always prescribed 
according to GOLD recommendations or other national 
guidelines,9,17–22 resulting in a substantial proportion of 
patients being treated with ICS unnecessarily and unduly 
exposed to the risk of serious side effects.
The objective of this study was to evaluate the current 
management of patients with COPD using real-life data 
generated in the UK primary-care setting. The study also 
includes a subset analysis of patients with moderate airflow 
limitation (FEV
1
 50–,80% predicted) as defined by NICE 
2010 guidelines, which corresponds to GOLD Stage 2.23 This 
population forms the majority of patients treated in primary 
care, and is therefore relevant in this analysis of prescribing 
patterns of UK general practitioners.
Methods
Data for patients with a diagnosis of COPD were extracted 
from the Optimum Patient Care Research Database (OPCRD) 
on May 20, 2013. Only data for patients with a COPD 
diagnosis (quality and outcomes framework diagnostic 
code),24 1 year of practice data prior to last data extraction and 
no leaving date, spirometry supportive of COPD diagnosis 
within 5 years of data extraction, and last data extraction 
date after 2009 were included in this retrospective analysis. 
Data from patients younger than 35 years at diagnosis were 
excluded.
The OPCRD is a quality-controlled, longitudinal, 
primary-care, respiratory-focused database containing 
anonymous data from general practices in the UK. The 
OPCRD has been approved by Trent Multicentre Research 
Ethics Committee for clinical research use (approval 
 reference 10/H0405/3). The database combines routine 
data from electronic patient records with linked patient-
reported data collected using disease-specific questionnaires. 
 Routine clinical data, including patient demographics, stan-
dard COPD comorbidities, exacerbation history, modified 
 Medical Research Council (mMRC) score,1 and current 
therapy, were extracted from primary-care practice man-
agement systems. In addition, a proportion of patients with 
relevant disease codes were invited to complete validated 
disease assessment questionnaires, sent via a secure mailing 
house, containing questions to calculate COPD Assessment 
Test (CAT)25 and mMRC scores. Questionnaire data were 
added to the database anonymously. The mMRC question-
naire and CAT are provided in the supplementary materials 
(Figures S2 and S3).
Data were analyzed according to GOLD group26 and pres-
ence or absence of a concomitant asthma diagnosis. In a  subset 
of patients with moderate airflow limitation,2,23 data were 
also analyzed by exacerbation history (moderate and severe 
exacerbation rate), mMRC score, and CAT score. mMRC 
scores were taken both from routine data (ie, abstracted 
from the medical record) and patient  questionnaires, with 
the most recent scores taking precedence. CAT scores were 
obtained from patient questionnaires. GOLD groups were 
calculated with mMRC rather than CAT scores, unless 
specified otherwise.
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Moderate and severe COPD exacerbations were defined 
as unscheduled hospital admission/emergency hospital atten-
dance for COPD (definite code) or lower respiratory-related 
events (ie, with a lower respiratory read code), or lower 
respiratory illnesses treated with antibiotics and/or acute 
use of oral steroids. Exacerbation rates were calculated for 
the year prior to most recent data extraction. Events were 
considered to be the result of the same exacerbation and only 
counted once if any of the three elements (hospitalization, 
oral steroid prescription, or lower respiratory tract infection 
consultation) occurred within 2 weeks of another.
Results
Patient selection
Data from 50,582 patients with COPD were extracted from 
339 practices. Among these patients, 24,957 (49.3%) met the 
inclusion criteria and were included in the analysis (Figure 1). 
Out of all the patients included in the analysis, 12,967 (52.0%) 
were sent questionnaires, which were returned by 6,088 
patients (46.9%). The GOLD Stage 2  subset included 13,557 
patients; 7,055 were sent a questionnaire, and 3,333 (47.2%) 
returned the questionnaire.
Demographics
The mean age of the total COPD population was 71.4 years; 
the majority of patients were ,75 years of age (59.7%), male 
(53.0%), and ex-smokers (56.2%) (Table 1). The distribution 
of patients according to GOLD stages was 15.8% in Stage 1, 
54.3% in Stage 2, 24.6% in Stage 3, and 5.3% in Stage 4. 
Based on degree of airflow limitation, symptoms (mMRC 
score), and history of exacerbations, the 23,294 (93.3%) 
patients with known mMRC score were identified as being 
in GOLD Group A (39.2%), Group B (20.0%), Group C 
(19.0%), or Group D (21.7%). Of the patients in the high-
risk groups, C and D, 57.6% and 59.2%, respectively, were 
categorized as high risk based on severity of airflow limita-
tion and not exacerbation history. The use of CAT score to 
assess symptoms resulted in a different distribution, with 
13.4%, 46.1%, 4.6%, and 35.9% of the 5,882 (23.6%) patients 
with known CAT score classified as Group A, B, C, or D, 
respectively. There were no major demographic differences 
across GOLD groups in terms of age, sex, and smoking status 
(Table 1). The prevalence of comorbidities was similar across 
GOLD groups, except for ischemic heart disease, which 
was more prevalent in patients in Groups B and D (Table 1). 
The combined percentage of overweight and obese patients 
was higher in Group B than in any other GOLD group.
Demographic characteristics of patients with GOLD 
Stage 2 COPD were similar to those of patients in the total 
COPD population (Table 2). The mean age was 70.9 years 
and 52.2% of patients were male. The majority of patients 
(54.7%) were ex-smokers. The most frequently occurring 
comorbidities in patients with GOLD Stage 2 COPD were 
the same as in the total COPD population. Patients with 
Exclusion criteria
Patient does not have 1 year
of data available (n=6,797)
Last extraction date prior
to 2009 (n=13,267)
Patient age <35 years at diagnosis
(n=430)
Patient did not have spirometry
reading within last 5 years
(n=5,131)
Inclusion criteria
Diagnosis of COPD using QOF
diagnostic code
Patient has 1 year of practice
data prior to last extraction date
and no leaving date
Patient has spirometry
supportive of COPD within
5 years of last extraction
Last extraction date at the
practice after 2009
COPD patients
n=50,582
OPCRD patients
n=809,717 (339 practices)
Registered at practice
n=43,785
Extraction post-2009
n=30,518
COPD diagnosis confirmed by
spirometry n=25,387
GOLD 2 patients
n=13,557 (of whom 3,333
returned a questionnaire)
Aged ≥35 years at diagnosis
n=24,957 (of whom 6,088
returned a questionnaire)
Figure 1 Patient selection.
Note: Data were extracted in May 2013.
Abbreviations: COPD, chronic obstructive pulmonary disease; gOlD, global Initiative for Chronic Obstructive lung Disease; OPCrD, Optimum Patient Care research 
Database; QOF, quality and outcomes framework.
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Table 1 Patient demographics for the total COPD population split by gOlD group
Total COPD  
population 
(n=24,957)
Unknown  
GOLD group 
(n=1,663)
GOLD A 
(n=9,140)
GOLD B 
(n=4,651)
GOLD C 
(n=4,437)
GOLD D 
(n=5,066)
Mean age,a years (sD) 71.4 (10.7) 69.7 (11.8) 69.7 (10.6) 74.1 (10.8) 70.7 (10.1) 73.1 (10.0)
 age ,60 3,352 (13.4) 326 (19.6) 1,540 (16.8) 468 (10.1) 567 (12.8) 451 (8.9)
 age 60–,75 11,558 (46.3) 745 (44.8) 4,484 (49.1) 1,801 (38.7) 2,273 (51.2) 2,255 (44.5)
 age 75 10,047 (40.3) 592 (35.6) 3,116 (34.1) 2,382 (51.2) 1,597 (36.0) 2,360 (46.6)
Male, n (%) 13,218 (53.0) 812 (48.8) 4,889 (53.5) 2,249 (48.4) 2,526 (56.9) 2,742 (54.1)
gOlD stage (gOlD 2013),  
n (%)
 1 3,937 (15.8) 414 (24.9) 2,136 (23.4) 888 (19.1) 305 (6.9) 194 (3.8)
 2 13,557 (54.3) 827 (49.7) 7,004 (76.6) 3,763 (80.9) 1,065 (24.0) 898 (17.7)
 3 6,137 (24.6) 338 (20.3) 0 (0) 0 (0) 2,669 (60.2) 3,130 (61.8)
 4 1,326 (5.3) 84 (5.1) 0 (0) 0 (0) 3,98 (9.0) 844 (16.7)
smoking status,b n (%)
 Known 24,947 (100.0) 1,663 (100) 9,138 (100) 4,651 (100) 4,434 (99.9) 5,061 (99.9)
 Current smoker 7,608 (30.5) 584 (35.1) 3,034 (33.2) 1,365 (29.3) 1,345 (30.3) 1,280 (25.3)
 ex-smoker 14,018 (56.2) 797 (47.9) 4,824 (52.8) 2,691 (57.9) 2,527 (57.0) 3,179 (62.8)
 nonsmoker 3,321 (13.3) 282 (17.0) 1,280 (14.0) 595 (12.8) 562 (12.7) 602 (11.9)
Body mass index,c n (%)
 Known 24,646 (98.8) 1,641 (98.7) 9,054 (99.1) 4,604 (99.0) 4,365 (98.4) 4,982 (98.3)
 Underweight 1,061 (4.3) 78 (4.8) 245 (2.7) 179 (3.9) 220 (5.0) 339 (6.8)
 normal weight 8,246 (33.5) 543 (33.1) 2,979 (32.9) 1,260 (27.4) 1,697 (38.9) 1,767 (35.5)
 Overweight 8,290 (33.6) 547 (33.3) 3,398 (37.5) 1,420 (30.8) 1,463 (33.5) 1,462 (29.3)
 Obese 7,049 (28.6) 473 (28.8) 2,432 (26.9) 1,745 (37.9) 985 (22.6) 1,414 (28.4)
Comorbidities,d n (%)
 anxiety or depression 7,621 (30.5) 573 (34.5) 2,644 (28.9) 1,607 (34.6) 1,205 (27.2) 1,592 (31.4)
 asthma 7,027 (28.2) 536 (32.2) 2,464 (27.0) 1,262 (27.1) 1,281 (28.9) 1,484 (29.3)
 Diabetes 4,592 (18.4) 268 (16.1) 1,545 (16.9) 1,028 (22.1) 764 (17.2) 987 (19.5)
  Chronic kidney disease  
(stage 3)
4,373 (17.5) 264 (15.9) 1,278 (14.0) 1,165 (25.0) 622 (14.0) 1,044 (20.6)
 Ischemic heart disease 4,114 (16.5) 229 (13.8) 1,145 (12.5) 1,132 (24.3) 572 (12.9) 1,036 (20.5)
 Osteoporosis 3,373 (13.5) 208 (12.5) 960 (10.5) 761 (16.4) 538 (12.1) 906 (17.9)
 rhinitis 3,099 (12.4) 230 (13.8) 1,171 (12.8) 521 (11.2) 586 (13.2) 591 (11.7)
 gerD 2,781 (11.1) 210 (12.6) 1,005 (11.0) 577 (12.4) 450 (10.1) 539 (10.6)
 heart failure 1,833 (7.3) 86 (5.2) 427 (4.7) 546 (11.7) 252 (5.7) 522 (10.3)
 history of pneumonia, n (%) 2,102 (8.4) 133 (8.0) 568 (6.2) 388 (8.3) 409 (9.2) 604 (11.9)
Notes: gOlD groups calculated based on mMrC score, FeV1, and history of exacerbations. For smoking status and body mass index, percentages were calculated based 
on the number of known patients, rather than all patients. aage at extraction; brecorded in OPCrD as nonsmoker, current smoker, or ex-smoker; crecorded in OPCrD and 
calculated as mass (kg)/height (m2); underweight ,18.5 kg/m2; normal weight between 18.5 and ,25 kg/m2, overweight between 25 and ,30 kg/m2, obese 30 kg/m2; 
dall comorbidities defined as having a diagnostic code in patients’ medical history.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; GERD, gastro-esophageal reflux disease; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; OPCRD, Optimum Patient Care Research Database; SD, standard deviation.
known GOLD groups (n=12,730) were identified as being 
in Group A (55.0%), Group B (29.6%), Group C (8.4%), or 
Group D (7.1%) based on mMRC score. Patients (n=3,227) 
were classified as being in Group A (18.7%), Group B 
(67.2%), Group C (2.0%), or Group D (12.2%) when symp-
toms were assessed using CAT score.
Demographic characteristics of patients who were 
responders and nonresponders to the study questionnaires 
are illustrated in the supplementary materials (Table S1) for 
total COPD population and GOLD Stage 2 subset. Overall, 
patients who returned the questionnaire, as compared with 
those who did not, tended to be slightly older (72.4 versus 
70.5 years) and were more likely to be male (56.1% versus 
52.5%) and ex-smokers (61.7% versus 52.1%) but less likely 
to be current smokers (24.7% versus 33.8%); differences in 
GOLD group categorization were minor. A similar pattern 
was evident for patients categorized at GOLD Stage 2 who 
did, versus did not, return the questionnaire (Table S1).
Clinical characteristics
Of the patients in the total COPD population, 61.0% had 
no exacerbations and 16.9% had two or more moderate or 
severe exacerbations in the year prior to data extraction. 
The majority of patients with no exacerbations were in 
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Group A (45.4%), while 25.9% of patients were classified 
as being in Groups C or D based on severity of airflow 
limitation (Figure 2). Of the patients with exacerba-
tions in the year prior to data extraction, 57.2% were in 
Groups C or D.
Patients with GOLD Stage 2 COPD displayed similar 
clinical characteristics to those in the overall cohort in 
terms of total exacerbation rate. In the GOLD Stage 2 
subset, 62.4% of patients had no exacerbations and 15.4% 
had two or more moderate or severe exacerbations in the 
Table 2 Patient demographics for the gOlD stage 2 population split by gOlD group
GOLD Stage 2  
population 
(n=13,557)
GOLD A 
(n=7,004)
GOLD B 
(n=3,763)
GOLD C 
(n=1,065)
GOLD D 
(n=898)
Mean age,a years (sD) 70.9 (10.9) 69.6 (10.5) 73.8 (10.8) 69.6 (10.2) 72.0 (10.7)
 age ,60 1,988 (14.7) 1,164 (16.6) 387 (10.3) 152 (14.3) 108 (12.0)
 age 60–,75 6,331 (46.7) 3,482 (49.7) 1,501 (39.9) 569 (53.4) 409 (45.5)
 age 75 5,238 (38.6) 2,358 (33.7) 1,875 (49.8) 344 (32.3) 381 (42.4)
Male, n (%) 7,082 (52.2) 3,881 (55.4) 1,890 (50.2) 517 (48.5) 381 (42.4)
smoking status,b n (%)
 Known 13,554 (100.0) 7,003 (100.0) 3,763 (100.0) 1,064 (99.9) 897 (99.9)
 Current smoker 4,413 (32.6) 2,361 (33.7) 1,135 (30.2) 355 (33.4) 257 (28.7)
 ex-smoker 7,414 (54.7) 3,744 (53.5) 2,200 (58.5) 570 (53.6) 516 (57.5)
 nonsmoker 1,727 (12.7) 898 (12.8) 428 (11.4) 139 (13.1) 124 (13.8)
Body mass index,c n (%)
 Known 13,412 (98.9) 6,931 (99.0) 3,720 (98.9) 1,052 (98.8) 888 (98.9)
 Underweight 452 (3.4) 188 (2.7) 154 (4.1) 40 (3.8) 32 (3.6)
 normal weight 4,186 (31.2) 2,265 (32.7) 1,030 (27.7) 345 (32.8) 275 (31.0)
 Overweight 4,628 (34.5) 2,577 (37.2) 1,153 (31.0) 396 (37.6) 230 (25.9)
 Obese 4,146 (30.9) 1,901 (27.4) 1,383 (37.2) 271 (25.8) 351 (39.5)
Comorbidities,d n (%)
 anxiety or depression 4,254 (31.4) 1,972 (28.2) 1,279 (34.0) 340 (31.9) 391 (43.5)
 asthma 3,743 (27.6) 1,840 (26.3) 1,015 (27.0) 326 (30.6) 299 (33.3)
 Diabetes 2,576 (19.0) 1,224 (17.5) 856 (22.7) 163 (15.3) 200 (22.3)
  Chronic kidney disease 
(stage 3)
2,381 (17.6) 969 (13.8) 927 (24.6) 164 (15.4) 198 (22.0)
 Ischemic heart disease 2,268 (16.7) 894 (12.8) 927 (24.6) 130 (12.2) 199 (22.2)
 rhinitis 1,754 (12.9) 863 (12.3) 413 (11.0) 213 (20.0) 144 (16.0)
 Osteoporosis 1,700 (12.5) 695 (9.9) 580 (15.4) 134 (12.6) 206 (22.9)
 gerD 1,536 (11.3) 741 (10.6) 437 (11.6) 131 (12.3) 131 (14.6)
 heart failure 965 (7.1) 333 (4.8) 448 (11.9) 53 (5.0) 89 (9.9)
history of pneumonia, n (%) 1,089 (8.0) 448 (6.4) 318 (8.5) 125 (11.7) 139 (15.5)
Notes: gOlD groups calculated based on mMrC score, FeV1, and history of exacerbations. For smoking status and body mass index, percentages were calculated based 
on the number of known patients, rather than all patients. aage at extraction; brecorded in OPCrD as nonsmoker, current smoker, or ex-smoker; crecorded in OPCrD and 
calculated as mass (kg)/height (m2); underweight ,18.5 kg/m2, normal weight between 18.5 and ,25 kg/m2, overweight between 25 and ,30 kg/m2, obese 30 kg/m2; 
dall comorbidities defined as having a diagnostic code in patients’ medical history.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; GERD, gastro-esophageal reflux disease; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; OPCRD, Optimum Patient Care Research Database; SD, standard deviation.
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year prior to data extraction. Of the patients with no exac-
erbations, 62.3% were classified as being in Group A and 
31.5% were classified as being in Group B. The majority 
of patients with exacerbations in the year prior to data 
extraction were in Group A (34.0%; Figure 2). However, 
38.5% of patients were classified as being in Groups C 
or D and experienced two or more exacerbations in the 
year previous to data extraction, despite having moderate 
airflow limitation.
In the total COPD population, among patients with 
a known mMRC score, the mean (standard deviation 
[SD]) mMRC score was 1.5 (1.0); 40.9% of patients 
had an mMRC score of 1 and 41.7% had a score 2. In 
the GOLD Stage 2 subset, among patients with a known 
mMRC score, the mean (SD) mMRC score was 1.3 (1.0); 
43.7% of patients had an mMRC score of 1 and 36.6% had 
a score 2. Among patients who returned a questionnaire 
and had a known CAT score, the mean (SD) CAT score 
was 17.1 (9.0) in the total COPD population and 16.3 (8.9) 
in the GOLD Stage 2 subset. Of the patients with a known 
CAT score, 79.0% and 76.4% had a CAT score 10 in the 
total COPD population and in the GOLD Stage 2 subset, 
respectively.
Current management
A similar proportion of patients in the total COPD  population 
(n=24,957) and GOLD Stage 2 subset (n=13,557) were not 
receiving pharmacologic treatment for COPD (17.0% and 
17.7%, respectively; Figure 3A and B). Approximately 
50% of patients in the total COPD population and GOLD 
Stage 2 subset were receiving ICS (Figure 3A and B), either 
in combination with a LABA (26.7% for both cohorts) or in 
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Figure 3 Current management for total COPD population (A) and gOlD stage 2 subset (B) by gOlD groups.
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combination with a LABA and a LAMA (23.2% and 19.9%, 
respectively). In both cohorts, ICS + LABA combinations 
were the most frequently used treatment in Groups A and B 
(Figure 3A and B). Of the total COPD population, 9.3% and 
5.1% of Group A and B patients were receiving ICS + LABA. 
Of the patients with GOLD Stage 2 COPD, 13.5% and 7.6% 
of Group A and B patients, respectively, were given ICS + 
LABA. A small proportion of patients across all GOLD 
groups were using LABA or LAMA monotherapy in the total 
COPD population (1.8% and 7.9%, respectively) and GOLD 
Stage 2 subset (2.0% and 8.2%; Figure 3A and B).
Current management was analyzed based on the presence 
or absence of a concomitant asthma diagnosis. Of the patients 
without a concomitant diagnosis of asthma in the total COPD 
population (n=17,930) and GOLD Stage 2 subset (n=9,814) 
53.7% and 50.2%, respectively, were receiving ICS. Among 
ICS-containing regimens, ICS + LAMA, ICS + LABA, and 
ICS + LABA + LAMA were the most frequently used treat-
ment options (total COPD population: 70.7%, 63.9%, and 
68.1%, respectively; GOLD Stage 2 subset: 68.8%, 63.2%, 
and 67.5%, respectively; Figure 4A and B).
gOlD stage 2 subset analyses
Additional analyses were conducted in the GOLD Stage 2 
subset. Figure 5 illustrates current management by mod-
erate and severe exacerbation rate. Among patients who 
experienced no exacerbations (n=8,458) or one exacerba-
tion (n=3,006) in the year prior to extraction, 49.0% and 
64.1%, respectively, were receiving ICS, either alone or 
in combination with long-acting bronchodilators. Of those 
patients receiving no treatment, 87.3% experienced no 
exacerbations in the year prior to data extraction, while 
of those patients receiving triple therapy (ICS + LABA + 
LAMA or ICS + LABA + leukotriene receptor antagonist) 
SA
BA
 (n=
2,5
99)
No
ne
 (n=
4,2
32)
SA
MA
 + 
SA
BA
 (n=
360
)
SA
MA
 (n=
174
)
LA
BA
 (n=
444
)
LA
MA
 (n=
1,9
65)
LA
BA
 + 
LA
MA
 (n=
196
)
ICS
 (n=
1,4
67)
ICS
 + 
LA
MA
 (n=
416
)
ICS
 + 
LA
BA
 (n=
6,6
68)
ICS
 + 
LA
BA
 + 
LA
MA
 (n=
5,7
93)
ICS
 + 
LA
BA
 + 
LA
MA
 + 
LT
RA
 (n=
245
)
ICS
 + 
LA
BA
 + 
LT
RA
 (n=
277
)
Oth
er 
the
rap
ies
 (n=
121
)
100
80
60
40
20
0
%
 o
f 
p
at
ie
n
ts
A
100
80
60
40
20
0
%
 o
f 
p
at
ie
n
ts
B
Total COPD population
SA
MA
 + 
SA
BA
 (n=
209
)
SA
BA
 (n=
1,6
01)
No
ne
 (n=
2,3
95)
SA
MA
 (n=
97)
LA
BA
 (n=
277
)
LA
MA
 (n=
1,1
10)
LA
BA
 + 
LA
MA
 (n=
115
)
ICS
 (n=
877
)
ICS
 + 
LA
MA
 (n=
234
)
ICS
 + 
LA
BA
 (n=
3,6
19)
ICS
 + 
LA
BA
 + 
LA
MA
 (n=
2,6
93)
ICS
 + 
LA
BA
 + 
LA
MA
 + 
LT
RA
 (n=
119
)
ICS
 + 
LA
BA
 + 
LT
RA
 (n=
150
)
Oth
er 
the
rap
ies
 (n=
61)
GOLD Stage 2 No Yes
No Yes
Asthma diagnosis
Asthma diagnosis
Figure 4 Current management by concomitant asthma diagnosis for total COPD population (A) and gOlD stage 2 subset (B).
Note: Other therapies include other combinations of ICs, laMa, laBa, saMa, saBa, lTra, and theophylline.
Abbreviations: COPD, chronic obstructive pulmonary disease; gOlD, global Initiative for Chronic Obstructive lung Disease; ICs, inhaled corticosteroids; laBa, 
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or quadruple therapy (ICS + LABA + LAMA + leukotriene 
receptor antagonist), more than 50% experienced one or more 
exacerbations in the year prior to extraction (Figure 5).
Further, current management in the GOLD Stage 2 
subset was analyzed based on mMRC and CAT scores to 
evaluate the proportion of patients experiencing symptoms 
while on treatment. An mMRC score 2 was recorded for 
22.7% of patients receiving no treatment, 35.4% of patients 
receiving LAMA monotherapy, and 35.6% and 50.2% of 
patients receiving ICS + LABA and ICS + LABA + LAMA, 
respectively (Figure 6A). A CAT score 10 was recorded 
for 66.7% of patients receiving no treatment, 74.5% of 
patients on LAMA monotherapy, and 74.4% and 81.9% of 
patients receiving ICS + LABA and ICS + LABA + LAMA, 
respectively (Figure 6B).
Discussion
The present study, one of the largest to evaluate real-life 
treatment patterns of COPD in the UK, indicates that COPD 
is often not managed in primary care according to the most 
recent recommendations and guidelines. In our analysis, 
a substantial proportion of patients with COPD did not receive 
any treatment despite experiencing symptoms or a history 
of exacerbations. Among patients receiving treatment, ICS 
were prescribed to patients irrespective of severity of airflow 
limitation, exacerbation history, and asthma diagnosis.
NICE recommends a LABA/ICS combination for patients 
with severe airflow limitation (FEV
1
 ,50% predicted) 
and/or persistent exacerbations/breathlessness2 whereas 
the GOLD 2014 strategy document currently recommends 
LABA/ICS combinations for patients in Groups C and D.1 
The only exception to these recommendations on the use of 
ICS is for patients with overlap phenotype of asthma and 
COPD, in whom ICS are indicated.9 Notably, a considerable 
proportion of patients in GOLD Groups A and B (mild-to-
moderate airflow limitation and low risk of exacerbations) 
in the total COPD population, as well as in the GOLD 
Stage 2 subset, were using ICS in combination with long-
acting bronchodilators; conversely, only a small proportion of 
these patients were treated exclusively with long-acting bron-
chodilators, either as mono- or combination therapy. Con-
sistent with this finding, approximately half of the patients 
who had not experienced an exacerbation in the year prior to 
data extraction were receiving ICS. The majority of patients 
without a concomitant diagnosis of asthma were also being 
treated with ICS, suggesting that ICS were overprescribed. 
In the total COPD population, 17% of patients were not 
receiving pharmacologic treatment for COPD. This is greater 
than the proportion of adults diagnosed with diabetes who 
have been reported to not use recommended oral medications 
or insulin (approximately 13%),27 but is lower compared 
with other chronic diseases such as multiple sclerosis and 
hypertension in which between one-third and two-thirds of 
patients have been reported to receive no approved treatment 
for their conditions.28–31
Our findings are supported by several studies analyzing 
the adherence to recommendations and guidelines for the 
management of COPD. Recently, data from a retrospec-
tive study revealed that most patients with COPD use ICS, 
irrespective of airflow limitation and exacerbation rate.32 In 
addition, data from the Adelphi Respiratory Disease Specific 
Programme® (Adelphi, Macclesfield, UK), a multinational, 
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cross-sectional market-research survey that generates data 
from current clinical practice, showed that a high proportion 
of low-risk patients are treated with a LABA/ICS.33 Studies 
in other European countries have also shown a tendency for 
ICS to be prescribed outside of current recommendations in 
COPD, indicating that poor adherence to treatment guidelines 
among primary-care physicians is widespread.9,20,22,34–37
Several factors can contribute to this disconnect between 
current real-life practice and evidence-based treatment 
recommendations. Two studies assessing the management 
of COPD in the US recently highlighted several barriers to 
implementing GOLD recommendations in primary care.38,39 
One important barrier identified by Perez et al38 was poor 
familiarity with GOLD recommendations, which was found to 
be associated with nonadherence to specific recommendations 
on ICS and long-acting bronchodilators. Further, the study by 
Salinas et al39 found that physicians who have difficulty assess-
ing response to therapy were less likely to adhere to recom-
mendations on long-acting bronchodilator use. As suggested 
by the authors of the study, this may be because long-acting 
bronchodilators produce subtle but meaningful improve-
ments, which can be difficult for physicians to recognize.39 
Moreover, physicians may not recognize a benefit of therapy 
in individual patients who have infrequent exacerbations, as 
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decreased frequency of exacerbations is an important measure 
of the efficacy of inhaled therapies. Indeed, in our study, 61% 
of the total population did not experience an exacerbation in 
the preceding year, including many patients classified as being 
in Groups C and D. This makes the assessment of treatment 
benefit difficult for all severities of COPD.
Difficulties in distinguishing between asthma and COPD 
in adults with airways disease, or in establishing when these 
two conditions coexist, could also play an important role. The 
CADRE (COPD and asthma diagnostic/management reassess-
ment) study among UK primary-care practices found a high 
rate of misdiagnosis among adults with airways disease, with a 
tendency to overdiagnose asthma and underdiagnose COPD.40 
A high proportion of patients diagnosed with asthma (54.3%) 
and mixed disease (45.4%) had their diagnosis changed, with 
the majority of them diagnosed with COPD after review. 
These findings indicate a lack of precision in diagnosing the 
‘chesty’ patient in primary care. Data from Spanish practices 
also confirm the difficulty of accurately diagnosing COPD in 
primary care. Primary-care physicians using clinical criteria 
and spirometry had difficulty reaching a diagnosis for up to 
20% of patients with chronic respiratory symptoms who were 
taking inhaled medication.37 The misdiagnosis of respiratory 
disease may lead to inadequate treatment and overuse of 
ICS21,22,37 particularly for patients with COPD.
The burden of symptoms reported by patients, which 
affects the physician-perceived severity of the disease, 
could also have a considerable impact on treatment choices. 
 Physicians may evaluate disease as more or less severe based 
on their overall clinical judgment rather than guidelines. 
Physicians may, therefore, be more willing to prescribe 
treatments outside of recommendations when confronted by 
symptomatic patients, resulting in ICS being prescribed for 
reasons other than severity of airflow limitation or exacerba-
tion risk. Indeed, a recent study of prescription drugs from UK 
general practices suggests that over 37% of COPD patients 
were overtreated (ie, according to GOLD 2009 recommen-
dations) and, of those, 96% were overtreated with ICS.41 As 
shown by our data, a substantial proportion of GOLD Stage 2 
patients in the UK are symptomatic on treatment, irrespective 
of their current management. In line with our findings, stud-
ies have suggested that many patients with moderate COPD 
may remain symptomatic despite LAMA monotherapy42–44 
or LABA/ICS treatment.45 Interestingly, our analysis sug-
gests that use of CAT, compared with mMRC, increased the 
number of patients in more symptomatic groups (Groups B 
and D), potentially because the CAT assessment considers 
not only dyspnea, but also other COPD symptoms and health 
status. This difference in GOLD group distribution depending 
on whether the mMRC score or CAT score is used highlights 
the difficulty facing primary-care physicians when making 
treatment decisions in real-life practice and illustrates how 
guidelines may only provide limited assistance.
It is important to note that in some cases the discordance 
between the current treatment recommendations and real-life 
clinical practice may be because of individual patients’ needs 
and comorbidities. Indeed, the NICE guidelines state that, 
“Treatment and care should take into account patients’ needs 
and preferences.”2 In addition, our study provides a snapshot 
of current practice and may reflect therapy that has been long-
standing and perceived as ‘effective’ by both the patient and 
physician. Thus, in some cases, depending on individual fac-
tors, it may be reasonable for patients to continue with existing 
therapy despite the updated treatment recommendations.
The baseline demographic and disease characteristics of the 
patients analyzed in our study provide interesting insights. The 
prevalence of cigarette smoking (approximately 30% in both 
the total COPD population and GOLD Stage 2 subset) is rather 
high considering that smoking cessation is the single most 
important intervention for all COPD patients who continue to 
smoke and has the greatest capacity to influence the natural 
history of the disease.1 The prevalence of anxiety or depression 
was also approximately 30% in both study populations. This 
may be expected to influence treatment outcomes because 
depression, in particular, is associated with poor compliance 
and negatively impacts on smoking cessation.46 The propor-
tion of patients with a history of pneumonia increased steadily 
from GOLD Groups A (6.2%) through D (11.9%), which is 
as expected and supports the reliability of GOLD Group cat-
egorization in the study. The majority of patients in Groups C 
and D were classified in these groups based on their severity 
of airflow limitation rather than exacerbation history, which is 
in accordance with the findings of other cohort studies.47
Although it is often reported that most COPD patients 
remain undiagnosed until their disease progresses to severe 
stages (FEV
1
 ,50% predicted),48–50 in our study more than 
50% of patients with spirometry-confirmed COPD had 
GOLD Stage 2 disease. This is consistent with other retro-
spective cohort studies in the UK. A recent analysis of a large 
database of primary-care COPD patients from 80 general 
practices across the UK showed that GOLD Stage 2 disease 
was present in 52% of patients.51 In an analysis of primary- 
and secondary-care data pooled from the OPCRD and the 
General Practice Research Database, 45% of patients with 
FEV
1
 data available had GOLD Stage 2 disease.52 The pro-
portion of patients with a lesser degree of airflow obstruction 
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at the time of COPD diagnosis increased over the 20-year 
study period, which may be due to increased use of diagnostic 
spirometry and recent COPD policy and practice guidance 
aimed to improve COPD diagnosis.52
Several study limitations must be considered when inter-
preting our results. As this is a retrospective analysis, it is 
not possible to conclude whether the treatment patterns are a 
response to symptoms or whether the symptoms show lack of 
response to treatment. Further, data on adherence have not been 
analyzed, so it cannot be established whether the presence of 
symptoms in patients on treatment is owing to inadequate dis-
ease control as a result of suboptimal treatment or poor adher-
ence to prescribed medications, or both. The analyses using 
CAT scores were conducted in a subset of patients because, 
unlike mMRC scores that were determined from questionnaire 
data or patient records, CAT scores could only be calculated 
from patient questionnaires, which were not available for all 
patients. Potential differences between the characteristics of 
patients who returned questionnaires and those who did not 
cannot be discounted as a possible source of bias.
In summary, this analysis of UK prescribing patterns 
indicates that COPD management choices do not usually 
follow GOLD recommendations and NICE guidelines, in 
particular those relating to the use of ICS and long-acting 
bronchodilators, which results in a substantial proportion of 
patients not being treated or not receiving the most appro-
priate medication. Further, it has been shown that many 
patients experience symptoms despite treatment. In light of 
the evidence provided by this analysis, evidence-based pre-
scription of COPD therapies should be encouraged among 
UK primary-care physicians in order to limit the risks and 
costs associated with undertreatment and overtreatment and 
to improve patient outcomes.
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Supplementary materials
Table S1 Characteristics of patients with COPD who were responders or nonresponders to the study questionnaires
Questionnaire returned No questionnaire returned  
(from patients who were sent  
questionnaires)
Total COPD  
population 
(n=6,088)
GOLD  
Stage 2 
(n=3,333) Total COPD  
population 
(n=6,879)
GOLD  
Stage 2 
(n=3,722)
Mean age,a years (sD) 72.4 (9.7) 72.0 (10.7) 70.5 (11.4) 70.0 (11.6)
 age ,60 542 (8.9) 325 (9.8) 1,165 (16.9) 698 (18.8)
 age 60–,75 2,981 (49.0) 1,639 (49.2) 3,087 (44.9) 1,672 (44.9)
 age 75 2,565 (42.1) 1,369 (41.1) 2,627 (38.2) 1,352 (36.3)
Male, n (%) 3,416 (56.1) 1,820 (54.6) 3,610 (52.5) 1,927 (51.1)
gOlD stage, n (%)
 1 899 (14.8) n/a 1,228 (17.9) n/a
 2 3,333 (54.7) n/a 3,722 (54.1) n/a
 3 1,549 (25.4) n/a 1,565 (22.8) n/a
 4 307 (5.0) n/a 364 (5.3) n/a
gOlD group (gOlD 2013), n (%)
 Unknown 26 (0.4) 15 (0.5) 917 (13.3) 446 (12.0)
 Known 6,062 (99.6) 3,318 (99.5) 5,962 (86.7) 3,276 (88.0)
 a 2,317 (38.2) 1,793 (54.0) 2,487 (41.7) 1,873 (57.2)
 B 1,298 (21.4) 1,054 (31.8) 1,103 (18.5) 877 (26.8)
 C 1,085 (17.9) 243 (7.3) 1,169 (19.6) 294 (9.0)
 D 1,362 (22.5) 228 (6.9) 1,203 (20.2) 232 (7.1)
smoking status,b n (%)
 Unknown 2 (,0.1) 0 3 (,0.1) 2 (,0.1)
 Known 6,086 (100.0) 3,333 (100.0) 6,876 (100.0) 3,720 (100.0)
 Current smoker 1,505 (24.7) 877 (26.3) 2,321 (33.8) 1,346 (36.2)
 ex-smoker 3,758 (61.7) 2,002 (60.1) 3,584 (52.1) 1,878 (50.5)
 nonsmoker 823 (13.5) 454 (13.6) 971 (14.1) 496 (13.3)
Body mass index,c n (%)
 Unknown 55 (0.9) 27 (0.8) 156 (2.3) 77 (2.1)
 Known 6,033 (99.1) 3,306 (99.2) 6,723 (97.7) 3,645 (97.9)
 Underweight 234 (3.9) 107 (3.2) 290 (4.3) 131 (3.6)
 normal weight 1,991 (33.0) 1,024 (31.0) 2,288 (34.0) 1,161 (31.9)
 Overweight 2,068 (34.3) 1,146 (34.7) 2,277 (33.9) 1,268 (34.8)
 Obese 1,740 (28.8) 1,029 (31.1) 1,868 (42.7) 1,085 (29.8)
Comorbidities,d n (%)
 anxiety or depression 1,768 (29.0) 982 (29.5) 2,168 (31.5) 1,196 (32.1)
 asthma 1,695 (27.8) 915 (27.5) 2,237 (32.5) 1,178 (31.6)
 Diabetes 1,049 (17.2) 589 (17.7) 1,250 (18.2) 679 (18.2)
 Chronic kidney disease (stage 3) 1,054 (17.3) 580 (17.4) 1,129 (16.4) 601 (16.1)
 Ischemic heart disease 986 (16.2) 541 (16.2) 1,093 (15.9) 617 (16.6)
 rhinitis 802 (13.2) 475 (14.3) 851 (12.4) 472 (12.7)
 Osteoporosis 793 (13.0) 405 (12.2) 834 (12.1) 429 (11.5)
 gerD 729 (12.0) 401 (12.0) 745 (10.8) 400 (10.7)
 heart failure 465 (7.6) 257 (7.7) 506 (7.4) 272 (7.3)
history of pneumonia 517 (8.5) 286 (8.6) 610 (8.9) 310 (8.3)
Notes: gOlD groups calculated based on mMrC score, FeV1, and history of exacerbations. For gOlD groups, smoking status and body mass index percentages were 
calculated based on the number of known patients, rather than all patients. aage at extraction; brecorded in OPCrD as non-smoker, current smoker, or ex-smoker; crecorded 
in OPCrD and calculated as mass (kg)/height (m2); underweight ,18.5 kg/m2, normal weight between 18.5 and ,25 kg/m2, overweight between 25 and ,30 kg/m2, obese 
30 kg/m2; dall comorbidities defined as having a diagnostic code in patients’ medical history.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; GERD, gastro-esophageal reflux disease; GOLD, Global 
initiative for chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; N/A, not applicable; OPCRD, Optimum Patient Care Research Database; 
sD, standard deviation.
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Figure S1 Model of symptom/risk evaluation of COPD.
Notes: When assessing risk, choose the highest risk according to gOlD stage or exacerbation history (one or more hospitalizations for COPD exacerbations should be 
considered high risk). gOlD 1, 2, 3, and 4 correspond to mild (FeV1 80% predicted), moderate (50% # FeV1 ,80% predicted), severe (30% # FeV1 ,50% predicted), 
and very severe (FeV1 ,30% predicted) airflow limitation, respectively. Reproduced from the Global Strategy for Diagnosis, Management and Prevention of COPD 2014. 
Copyright © global Initiative for Chronic Obstructive lung Disease (gOlD), all rights reserved. available from http://www.goldcopd.org.1
Abbreviations: CaT, COPD assessment Test; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; gOlD, global Initiative for 
Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council.
Figure S2 Modified Medical Research Council questionnaire for assessing the severity of breathlessness.
reproduced from the global strategy for Diagnosis, Management and Prevention of COPD 2014. Copyright © global Initiative for Chronic Obstructive lung Disease 
(gOlD), all rights reserved. available from http://www.goldcopd.org.1
Abbreviation: mMrC, modified Medical Research Council.
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Figure S3 COPD assessment Test.
Notes: The COPD assessment Test score is calculated as the sum of the responses present. If more than two responses are missing, a score cannot be calculated; when 
one or two items are missing their scores can be set to the average of the nonmissing item scores. reproduced with permission. COPD assessment Test and CaT logo is 
a trade mark of the glaxosmithKline group of companies. © 2009 glaxosmithKline group of companies. all rights reserved.2
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